ArticlePrzeglad gastroenterologiczny2022
Prognostic significance of α-fetoprotein in gastric adenocarcinoma.
Article in Przeglad gastroenterologiczny, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 5 citations in OpenAlex.
- Dual-positive gastric cancer co-expressing AFP and CEA: an aggressive subtype defined by unique clinical and biological profiles.Clinical and experimental medicine · 2026Review
- Molecular pathogenesis and novel therapeutic avenues in alpha-fetoprotein-producing gastric cancer.Frontiers in oncology · 2026Review
- Relationship between imaging, clinical, pathological features, and alpha-fetoprotein-producing gastric cancer: diagnostic performance of enhanced CT conventional features.Quantitative imaging in medicine and surgery · 2025Article
- The combination of CA125, CA199, CEA, and AFP is an effective diagnostic biomarker for gastric cancer in elderly individuals.World journal of surgical oncology · 2025Article
- Prognostic impact and reasons for variability by tumor location in gastric cancer.World journal of gastroenterology · 2024Article
- Inflammation-related markers and prognosis of alpha-fetoprotein producing gastric cancer.World journal of gastrointestinal oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: α-fetoprotein (AFP)-producing gastric carcinoma is a rare type of gastric cancer. Compared with other types, it is more aggressive and prone to liver metastases. Aim: To investigate the prognostic characteristics of AFP in patients with gastric adenocarcinoma. Material and methods: Our study included 391 patients diagnosed with gastric adenocarcinoma, who were admitted between 2006 and 2019. For all patients, demographic characteristics, location of the lesion, levels of AFP, CEA, and CA19-9, pathology diagnosis, results of operation, and survival status were recorded. Results: In our study, 68.3% of the patients were male, and the mean age was 62.76 years. In 66 (16.9%) patients, AFP level (cut-off = 8.2 ng/dl) was higher than normal. A total of 26 cases were with AFP > 100 ng/ml. 92.3% of cases with positive AFP gastric cancer were stage 4, and liver metastasis was detected in 80.8%. No significant difference was found between groups with AFP levels of < 100 ng/ml and ≥ 100 ng/ml in terms of gender, location of the lesion, or stage of the tumour. An AFP value higher than 100 ng/ml was significantly associated with liver metastasis, pathological diagnoses, and metastasis status. There was a significant difference in mortality between AFP > 100 ng/ml and age. Conclusions: Predictors with high predictive value are needed for early diagnosis and screening of gastric cancer. We thought that comprehensive studies on this subject would contribute to the literature and reduce the mortality and economic losses by determining the prognosis of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.